Skip to main content
. 2021 Mar 2;10:594141. doi: 10.3389/fonc.2020.594141

Figure 5.

Figure 5

Effects of lead agents in paclitaxel-resistant prostate cancer cells. (A) Cytotoxic effects of paclitaxel and fenbendazole (FBZ) in paclitaxel-resistant prostate cancer cells. FBZ-DNTC was significantly (p < 0.001) more cytotoxic than paclitazel alone in both cell lines for doses ≥1 µM. (B) Comparison of ED50 of agents in paclitaxel-sensitive and -resistant cell lines. (C) Percent apoptosis induced by each agent in paclitaxel-sensitive and -resistant cell lines, as measured by annexin V staining. Comparing the data in (B, C), FBZ was the only drug significantly (p<0.05) more cytotoxic/apoptotic in both paclitaxel-resistant prostate cancer cell lines. (D) Relative growth of subcutaneous PC-3TxR tumors after treatment with DNTC alone, paclitaxel or FBZ in DNTC. Treatment was given three times per week for three weeks. FBZ significantly inhibited tumor growth compared to paclitaxel or vehicle, N=10 per group, p < 0.01. (E) Average of tumor size from each treatment group at the end of study. Data shown are mean ± 95% confidence interval, N=10 per group, p < 0.01.